SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novartis -- Ignore unavailable to you. Want to Upgrade?


To: Jack Hartmann who wrote (273)3/28/2000 8:41:00 PM
From: Jack Hartmann  Read Replies (1) | Respond to of 296
 
Swiss Business Briefs: Novartis Eye Therapy Advances
Dow Jones Newswires
3/28/2000
ZURICH -- Novartis AG (Z.NOV) said Phase III study of its Visudyne therapy produced benefits for patients with two vision conditions, age-related macular degeneration and choroidal neovascularization. Visudyne therapy is being jointly developed by Ciba Vision, a unit of Novartis, and QLT PhotoTherapeutics Inc (QLT).

No further ifo, but looks good.
Jack